
Cite this as: Hui-ying WANG, Yu DAI, Jiao-li WANG, Xu-yan YANG, Xin-guo JIANG, 2015. Anti-CD69 monoclonal antibody treatment inhibits airway inflammation in a mouse model of asthma. *Journal of Zhejiang University-Science B (Biomedicine & Biotechnology).* **16**(7):622-631. [doi:10.1631/jzus.B1400285]

Anti-CD69 monoclonal antibody treatment inhibits airway inflammation in a mouse model of asthma


Key words: **Cluster of differentiation 69 (CD69), Eosinophil, Interleukin-5 (IL-5), Asthma**

Research Summary

The present study demonstrated the therapeutic effect of anti-CD69 mAb in eliminating established airway inflammation asthmatic mice from the following aspects:



- **Eliminate airway eosinophil infiltration**
- **Inhibit airway mucus production**
- **Reduce BALF IL-5 level**
- **Inhibit airway hyper-responsiveness**





JCUS-B

Innovation points

●**Identification** of a new antibody that could inhibit the established airway inflammation of asthmatic mice

● **Comparison** of the therapeutic efficiency of anti-CD69mAb to DXM, the classic first-line drug for asthma

● **Introduction a potential** potential alternative regimen for the therapy of asthma and its exacerbation.




Figure 4

JZUS-B